What are ADC's

Our services

ADC Review
is made possible by:


Study Title
Brentuximab Vedotin (Recombinant) for IV Infusion – Special Drug Use Surveillance (All-case Surveillance) “Relapsed or Refractory CD30+ Hodgkin’s Lymphoma or Anaplastic Large Cell Lymphoma” (NCT02139592)

Trial Description
The purpose of this study is to evaluate the safety of the  antibody-drug conjugate or ADC brentuximab vedotin (recombinant) for IV infusion (Adcetris® IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin lymphoma or anaplastic large cell lymphoma (ALCL) in the routine clinical setting, as well as to collect efficacy information for reference.

This trial is sponsored by Takeda Pharmaceuticals. [1]

Study Data

  • Condition:
    • Relapsed or Refractory CD30+ Hodgkin Lymphoma
    • Anaplastic Large Cell Lymphoma (ALCL)
  • Interventions:
  • Phase: 0
  • Estimated Enrollment: 140
  • Start: April 2014
  • Estimated Completion: June 2017
  • Last verified: May 2014

Study Schematic


Click here to Return to Drug map

Last Editorial review: July 15, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar